DZ2546A1 - Sels de sertraline et formes posologiques de sertraline à libération prolongée et procédé pour leur préparation. - Google Patents

Sels de sertraline et formes posologiques de sertraline à libération prolongée et procédé pour leur préparation.

Info

Publication number: DZ2546A1
Authority: DZ; Algeria
Prior art keywords: sertraline; preparation; dosage forms; sustained release; release dosage
Prior art date: 1997-07-01

Application number

DZ980156A

Other languages

English (en)

Inventor

Mary Tanya Am Ende

William John Curatolo

Hylar Lewis Friedman

Ravi Myshore Shanker

Scott Max Herbig

Dwayne Thomas Friesen

James Wets West

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-01

Filing date

1998-06-30

Publication date

2003-02-08

1998-06-30 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-02-08 Application granted granted Critical

2003-02-08 Publication of DZ2546A1 publication Critical patent/DZ2546A1/fr

Links

VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical class C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 title 2
239000002552 dosage form Substances 0.000 title 1
238000000034 method Methods 0.000 title 1
229960002073 sertraline Drugs 0.000 title 1
238000013268 sustained release Methods 0.000 title 1
239000012730 sustained-release form Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Hematology (AREA)
Obesity (AREA)
Immunology (AREA)
Addiction (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DZ980156A 1997-07-01 1998-06-30 Sels de sertraline et formes posologiques de sertraline à libération prolongée et procédé pour leur préparation. DZ2546A1 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US5142097P	1997-07-01	1997-07-01
US5141497P	1997-07-01	1997-07-01
US5149897P	1997-07-01	1997-07-01
US5140297P	1997-07-01	1997-07-01

Publications (1)

Publication Number	Publication Date
DZ2546A1 true DZ2546A1 (fr)	2003-02-08

Family

ID=27489408

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ980156A DZ2546A1 (fr)	1997-07-01	1998-06-30	Sels de sertraline et formes posologiques de sertraline à libération prolongée et procédé pour leur préparation.

Country Status (32)

Country	Link
US (1)	US6517866B1 (fr)
EP (1)	EP0999830A1 (fr)
JP (1)	JP2000514101A (fr)
KR (2)	KR100412327B1 (fr)
CN (1)	CN1256085C (fr)
AP (1)	AP1526A (fr)
AR (2)	AR015919A1 (fr)
AU (1)	AU739261B2 (fr)
BG (1)	BG103915A (fr)
BR (1)	BR9810403A (fr)
CA (1)	CA2290966C (fr)
CO (1)	CO4940402A1 (fr)
DZ (1)	DZ2546A1 (fr)
EA (1)	EA002482B1 (fr)
HR (1)	HRP980379B1 (fr)
HU (1)	HUP0002296A3 (fr)
ID (1)	ID23503A (fr)
IL (2)	IL133080A0 (fr)
IS (1)	IS5265A (fr)
MY (1)	MY129175A (fr)
NO (1)	NO996518L (fr)
NZ (2)	NZ501251A (fr)
OA (1)	OA11245A (fr)
PA (1)	PA8454401A1 (fr)
PE (1)	PE88699A1 (fr)
PL (1)	PL337806A1 (fr)
SK (1)	SK180499A3 (fr)
TN (1)	TNSN98125A1 (fr)
TR (1)	TR199903280T2 (fr)
TW (1)	TWI241188B (fr)
UY (1)	UY25067A1 (fr)
WO (1)	WO1999001121A1 (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040208926A1 (en) *	1997-07-01	2004-10-21	Pfizer Inc	Solubilized sertraline compositions
AU3024399A (en) *	1998-04-03	1999-10-25	Bm Research A/S	Controlled release composition
US6706283B1 (en) *	1999-02-10	2004-03-16	Pfizer Inc	Controlled release by extrusion of solid amorphous dispersions of drugs
EP1178780B1 (fr) *	1999-05-20	2007-07-18	ELAN CORPORATION, Plc	Preparations d'inhibiteurs specifiques du recaptage de la serotonine a liberation multiparticulaire regulee
IE990406A1 (en)	1999-05-20	2000-12-27	Elan Corp Plc	Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
PL211402B1 (pl)	1999-09-03	2012-05-31	Apbi Holdings	Zastosowanie dapoksetyny do leczenia lub zwalczania przedwczesnej ejakulacji
GB9923045D0 (en) *	1999-09-29	1999-12-01	Novartis Ag	New oral formulations
CA2395231C (fr) *	1999-12-23	2006-08-15	Pfizer Products Inc.	Forme de dosage d'un medicament stratifie entraine par un hydrogel
US6620431B1 (en) *	2000-04-17	2003-09-16	Charles Signorino	Shellac film coatings providing release at selected pH and method
US20030086972A1 (en) *	2000-08-09	2003-05-08	Appel Leah E.	Hydrogel-driven drug dosage form
MXPA03001771A (es)	2000-08-30	2003-06-04	Pfizer Prod Inc	Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento.
US6482440B2 (en) *	2000-09-21	2002-11-19	Phase 2 Discovery, Inc.	Long acting antidepressant microparticles
SE0004671D0 (sv)	2000-12-15	2000-12-15	Amarin Dev Ab	Pharmaceutical formulation
JP2002212062A (ja) *	2001-01-24	2002-07-31	Teijin Ltd	遅延放出制御組成物
US20040076682A1 (en) *	2001-02-15	2004-04-22	Toshiyuki Kohzaki	Novel ophthalmic compositions
WO2002085335A1 (fr) *	2001-04-18	2002-10-31	Nostrum Pharmaceuticals Inc.	Nouvel enrobage de composition pharmaceutique a liberation lente
EP1416922A1 (fr) *	2001-07-16	2004-05-12	AstraZeneca AB	Formulation pharmaceutique a base d'un inhibiteur de la pompe a proton et d'antiacides
WO2003024430A1 (fr) *	2001-09-21	2003-03-27	Egalet A/S	Systeme a liberation de polymere de morphine
EP1429739A1 (fr)	2001-09-21	2004-06-23	Egalet A/S	Systeme de liberation a base de polymere
CA2447984A1 (fr) *	2001-09-28	2003-04-03	Mcneil-Ppc, Inc.	Formes dosifiees presentant un noyau interne et une couche externe de formes differentes
US7005138B2 (en) *	2001-12-21	2006-02-28	Duramed Pharmaceuticals, Inc.	Method of systematically delivering SSRIs
US7670612B2 (en)	2002-04-10	2010-03-02	Innercap Technologies, Inc.	Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20100189797A1 (en)	2002-06-10	2010-07-29	Julien Mendlewicz	Oral antidepressant formulation
US20050226926A1 (en) *	2002-07-25	2005-10-13	Pfizer Inc	Sustained-release tablet composition of pramipexole
AU2003272461A1 (en) *	2002-09-16	2004-04-30	Sepracor Inc.	TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE
US20040220153A1 (en) *	2002-09-24	2004-11-04	Jost-Price Edward Roydon	Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
CA2415154C (fr) *	2002-12-24	2009-06-16	Biovail Laboratories Inc.	Preparations a liberation modifiee contenant des inhibiteurs selectifs de la recapture de la serotonine
WO2004065348A1 (fr)	2003-01-23	2004-08-05	Pfizer Products Inc.	Sels pharmaceutiquement acceptables de sertraline et compositions pharmaceutiques correspondantes
WO2004073614A2 (fr) *	2003-02-14	2004-09-02	Combinatorx, Incorporated	Polytherapie servant au traitement de troubles immuno-inflammatoires
EP1610767B1 (fr)	2003-03-26	2011-01-19	Egalet A/S	Systeme de liberation regulee de morphine
EP1613333A1 (fr) *	2003-04-04	2006-01-11	Pharmacia Corporation	Tablettes comprimees orales de formulations multiparticulaires a liberation prolongee
CN102525993B (zh)	2003-04-24	2017-04-12	佳高泰克有限公司	具有限定内核几何形状的缓释片剂
WO2005000786A1 (fr)	2003-05-23	2005-01-06	Transform Pharmaceuticals, Inc.	Compositions de sertraline
KR101087464B1 (ko) *	2003-08-08	2011-11-25	밸리언트 인터내셔널(바베이도스) 에스알엘	부프로피온 히드로클로라이드의 개질 방출형 정제
KR101161813B1 (ko) *	2003-11-04	2012-07-05	씨아이피엘에이 엘티디.	선택적인 세로토닌 재흡수 억제제의 다형체들의 제조 방법
PE20060003A1 (es) *	2004-03-12	2006-03-01	Smithkline Beecham Plc	Formulacion farmaceutica polimerica para moldear por inyeccion
KR100772980B1 (ko) *	2004-04-01	2007-11-02	한미약품 주식회사	메트포르민의 경구투여용 서방성 제제
US20050232911A1 (en) *	2004-04-19	2005-10-20	Schreiber Brian D	Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
ITMI20041295A1 (it) *	2004-06-25	2004-09-25	Cosmo Spa	Composizioni farmaceutiche antimicrobiche orali
NZ553587A (en)	2004-08-13	2010-12-24	Boehringer Ingelheim Int	Extended release tablet formulation containing pramipexole or a pharmacutically acceptable salt thereof
KR100920856B1 (ko) *	2004-11-30	2009-10-09	(주)아모레퍼시픽	선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법
WO2006072878A1 (fr) *	2005-01-07	2006-07-13	Ranbaxy Laboratories Limited	Formes posologiques orales de sertraline possedant une taille de particule controlee, et leurs procedes de preparation
US20080274183A1 (en) *	2005-02-04	2008-11-06	Phillip Michael Cook	Thermoplastic articles containing a medicament
EP1858493A4 (fr) *	2005-03-14	2010-12-01	Sun Pharmaceutical Ind Ltd	Systeme d'administration de medicament par voie orale
CA2611081C (fr) *	2005-06-03	2016-05-31	Egalet A/S	Systeme d'administration de medicaments permettant d'administrer des substances actives dispersees dans un milieu de dispersion
US8747897B2 (en)	2006-04-27	2014-06-10	Supernus Pharmaceuticals, Inc.	Osmotic drug delivery system
US7893053B2 (en) *	2006-06-16	2011-02-22	Theracos, Inc.	Treating psychological conditions using muscarinic receptor M1 antagonists
SG174026A1 (en)	2006-08-03	2011-09-29	Nitec Pharma Ag	Delayed-release glucocorticoid treatment of rheumatoid disease
EP2104493A2 (fr) *	2007-01-16	2009-09-30	Egalet A/S	Utilisation (i) d'un polyglycol et (ii) d'une substance médicamenteuse active dans la préparation d'une composition pharmaceutique destinée (i) à réduire le risque de libération massive induite par l'alcool et/ou (ii) à réduire le risque de toxicomanie médicamenteuse
AU2008258596B2 (en)	2007-06-04	2013-02-14	Egalet Ltd	Controlled release pharmaceutical compositions for prolonged effect
WO2009034431A2 (fr)	2007-09-10	2009-03-19	Pfizer Inc.	Formes posologiques à libération contrôlée de la varenicline
CA2734095A1 (fr) *	2008-08-14	2010-02-18	Bioneer A/S	Comprimes enrobes avec une surface de degradation residuelle dans le temps
DE102008051572A1 (de)	2008-09-05	2010-03-11	Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh	Herstellung von Phosphatbindern und auf diese Weise hergestellte Phosphatbinder
AU2008243202B2 (en) *	2008-11-11	2015-08-20	Cosmo Technologies Ltd	Oral antimicrobial pharmaceutical compositions
NZ594207A (en)	2009-02-06	2013-03-28	Egalet Ltd	Immediate release composition resistant to abuse by intake of alcohol
WO2010149169A2 (fr)	2009-06-24	2010-12-29	Egalet A/S	Formulations à libération contrôlée
CA2780274C (fr)	2009-11-09	2018-06-26	Spotlight Technology Partners Llc	Hydrogels fragmentes
WO2011057131A1 (fr)	2009-11-09	2011-05-12	Spotlight Technology Partners Llc	Hydrogels à base de polysaccharide
US9549899B2 (en)	2012-07-06	2017-01-24	Egalet Ltd.	Abuse deterrent pharmaceutical compositions for controlled release
JP6041823B2 (ja)	2013-03-16	2016-12-14	ファイザー・インク	トファシチニブの経口持続放出剤形
WO2016020936A2 (fr) *	2014-07-21	2016-02-11	Patel Jayendrakumar Dasharathlal	Nouvelle forme posologique pharmaceutique orale de rétention gastrique
CN104402705B (zh) *	2014-11-04	2017-04-12	成都理工大学	球形柠檬酸钙及其制备方法和应用
JP6455293B2 (ja) *	2015-04-21	2019-01-23	ニプロ株式会社	セルトラリン及び／又はその薬学上許容しうる塩を含む製剤
DK3592337T3 (da) *	2017-03-08	2023-09-18	Cinrx Pharma Llc	Farmaceutiske formuleringer af phloroglucinol og trimethylphloroglucinol
EP3675656B1 (fr) *	2017-10-05	2021-11-10	Purac Biochem B.V.	Poudre de lactate et son procédé de préparation
CN109432038A (zh) *	2018-12-28	2019-03-08	乐普制药科技有限公司	一种含有盐酸舍曲林的肠溶片剂及其制备方法
GB201914779D0 (en) *	2019-10-11	2019-11-27	Oxford Medical Products Ltd	Polymer compositions
EP4311113B1 (fr)	2022-07-21	2026-04-08	Rohde & Schwarz GmbH & Co. KG	Récepteur de fréquence radio et son procédé de fonctionnement
CN118522388B (zh) *	2024-07-25	2024-10-11	北京科技大学	二元复配有机缓蚀剂优化方法、装置、设备及介质
CN119915068B (zh) *	2025-04-01	2025-07-08	烟台华孚制冷设备有限公司	一种盘式制冷装置及冰淇淋机

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4536518A (en) *	1979-11-01	1985-08-20	Pfizer Inc.	Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
DK150008C (da)	1981-11-20	1987-05-25	Benzon As Alfred	Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4797286A (en)	1985-11-12	1989-01-10	Eli Lilly And Company	Orally administerable sustained release pharmaceutical formulations
US4847092A (en)	1985-11-12	1989-07-11	Eli Lilly And Company	Orally administerable sustained release pharmaceutical formulations
US5112619A (en)	1985-11-12	1992-05-12	Eli Lilly And Company	Orally administerable sustained release pharmaceutical formulation
US4803076A (en)	1986-09-04	1989-02-07	Pfizer Inc.	Controlled release device for an active substance
DE3700420A1 (de)	1986-12-22	1988-07-07	Efka Werke Kiehn Gmbh Fritz	Tabakerzeugnis fuer die selbstverfertigung einer zigarette, insbesondere filter-zigarette
US5135947A (en)	1987-04-09	1992-08-04	Eli Lilly And Company	1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
US4777288A (en)	1987-06-11	1988-10-11	Pfizer Inc.	Process for preparing a 4,4-diphenylbutanoic acid derivative
US4839104A (en)	1987-06-11	1989-06-13	Pfizer, Inc.	Process for preparing sertraline intermediates
US4792448A (en)	1987-06-11	1988-12-20	Pfizer Inc.	Generic zero order controlled drug delivery system
US4971998A (en)	1987-10-22	1990-11-20	Massachusetts Institute Of Technology	Methods for treating the premenstrual or late luteal phase syndrome
US4876282A (en)	1987-11-25	1989-10-24	Eli Lilly And Company	1-Phenylalkylamines as selective serotonin uptake inhibitors
US4855500A (en)	1988-05-04	1989-08-08	Pfizer Inc.	Process for preparing a ketimine
US5026707A (en)	1988-05-23	1991-06-25	Eli Lilly And Company	Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
IL91398A (en)	1988-08-30	1994-05-30	Pfizer	Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
IL109647A (en)	1989-02-27	1997-04-15	Lilly Co Eli	Intermediate compounds for ring-substituted 2-amino-1, 2, 3, 4-tetra- hydronaphthalenes and 3-aminochromanes
US4981870A (en)	1989-03-07	1991-01-01	Pfizer Inc.	Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US4983401A (en)	1989-05-22	1991-01-08	Kinaform Technology, Inc.	Sustained release pharmaceutical preparations having pH controlled membrane coatings
US4940731A (en)	1989-08-30	1990-07-10	Pfizer Inc.	Method of treating premature ejaculation using sertraline
ATE96999T1 (de)	1989-08-30	1993-11-15	Pfizer	Verwendung von sertralin zur behandlung von abhaengigkeiten von chemischen stoffen.
US5130338A (en)	1989-08-30	1992-07-14	Pfizer Inc.	Method of treating chemical dependencies using sertraline
US4962128A (en) *	1989-11-02	1990-10-09	Pfizer Inc.	Method of treating anxiety-related disorders using sertraline
AU8072691A (en)	1990-06-28	1992-01-23	Beecham Group Plc	Pharmaceutical preparations
DE69107461T2 (de)	1990-08-07	1995-06-22	Pfizer	Verwendung von interfacial polymerisierten membranen in abgabevorrichtungen.
PT98628A (pt)	1990-08-09	1992-06-30	Massachusetts Inst Technology	Processo de composicoes farmaceuticas a base de por exemplo sertralina
US5104899A (en)	1990-08-13	1992-04-14	Sepracor, Inc.	Methods and compositions for treating depression using optically pure fluoxetine
JPH06502854A (ja)	1990-11-24	1994-03-31	ビーチャム・グループ・パブリック・リミテッド・カンパニー	老年痴呆、過食症、片頭痛または食欲不振の治療用のパロキセチンの使用
DK0498590T3 (da)	1991-02-08	1997-05-05	Lilly Co Eli	Ringsubstituerede 2-amino-1,2,3,4-tetrahydronaphthalener
WO1992018005A1 (fr)	1991-04-16	1992-10-29	National Institutes Of Health	Procede de traitement de la trichotillomanie et de l'onychophagie
US5196607A (en)	1992-02-14	1993-03-23	Pfizer Inc.	Process for preparing ketone enantiomer
ATE173159T1 (de)	1992-03-25	1998-11-15	Depomed Systems Inc	Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
US5518730A (en)	1992-06-03	1996-05-21	Fuisz Technologies Ltd.	Biodegradable controlled release flash flow melt-spun delivery system
US5248699A (en)	1992-08-13	1993-09-28	Pfizer Inc.	Sertraline polymorph
US6440457B1 (en)	1993-05-27	2002-08-27	Alza Corporation	Method of administering antidepressant dosage form
IE930485A1 (en)	1993-06-28	1994-12-28	Hemisphere Ltd	Antidepressant agents with a rapid onset of action
US5597826A (en)	1994-09-14	1997-01-28	Pfizer Inc.	Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
ATE214276T1 (de)	1994-09-19	2002-03-15	Du Pont Pharm Co	Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
EP0768083B1 (fr)	1995-07-17	2003-03-26	Pfizer Inc.	Sertraline pour le traitement des patients post-infarction myocardique
GB9514842D0 (en)	1995-07-20	1995-09-20	Smithkline Beecham Plc	Novel formulation
CN1494907A (zh)	1996-03-25	2004-05-12		治疗疼痛的药物组合物
ZA97976B (en) *	1996-04-05	1997-08-18	Alza Corp	Uniform drug delivery theraphy.
US5741807A (en)	1996-09-27	1998-04-21	Cytos Pharmaceuticals, L.P.	Histidine compositions and methods for treating or preventing infectious and non-infectious diarrheas
US6590083B1 (en)	1999-04-16	2003-07-08	Ortho-Mcneil Pharmaceutical, Inc.	Ketolide antibacterials

1998
- 1998-06-15 HU HU0002296A patent/HUP0002296A3/hu unknown
- 1998-06-15 EA EA199900964A patent/EA002482B1/ru not_active IP Right Cessation
- 1998-06-15 EP EP98923020A patent/EP0999830A1/fr not_active Withdrawn
- 1998-06-15 ID IDW991704A patent/ID23503A/id unknown
- 1998-06-15 SK SK1804-99A patent/SK180499A3/sk unknown
- 1998-06-15 IL IL13308098A patent/IL133080A0/xx unknown
- 1998-06-15 NZ NZ501251A patent/NZ501251A/en unknown
- 1998-06-15 US US09/380,897 patent/US6517866B1/en not_active Expired - Fee Related
- 1998-06-15 CN CNB988066963A patent/CN1256085C/zh not_active Expired - Fee Related
- 1998-06-15 NZ NZ513456A patent/NZ513456A/xx unknown
- 1998-06-15 IL IL15233098A patent/IL152330A0/xx unknown
- 1998-06-15 PL PL98337806A patent/PL337806A1/xx unknown
- 1998-06-15 WO PCT/IB1998/000934 patent/WO1999001121A1/fr not_active Ceased
- 1998-06-15 KR KR10-1999-7012073A patent/KR100412327B1/ko not_active Expired - Fee Related
- 1998-06-15 JP JP11506775A patent/JP2000514101A/ja active Pending
- 1998-06-15 KR KR10-2003-7002633A patent/KR100446366B1/ko not_active Expired - Fee Related
- 1998-06-15 CA CA002290966A patent/CA2290966C/fr not_active Expired - Fee Related
- 1998-06-15 BR BR9810403-9A patent/BR9810403A/pt not_active Application Discontinuation
- 1998-06-15 AU AU75449/98A patent/AU739261B2/en not_active Ceased
- 1998-06-15 TR TR1999/03280T patent/TR199903280T2/xx unknown
- 1998-06-25 TW TW087110253A patent/TWI241188B/zh not_active IP Right Cessation
- 1998-06-25 AP APAP/P/1998/001281A patent/AP1526A/en active
- 1998-06-26 PE PE1998000572A patent/PE88699A1/es not_active Application Discontinuation
- 1998-06-29 MY MYPI98002948A patent/MY129175A/en unknown
- 1998-06-29 UY UY25067A patent/UY25067A1/es not_active IP Right Cessation
- 1998-06-29 AR ARP980103148A patent/AR015919A1/es not_active Application Discontinuation
- 1998-06-30 PA PA19988454401A patent/PA8454401A1/es unknown
- 1998-06-30 DZ DZ980156A patent/DZ2546A1/fr active
- 1998-06-30 TN TNTNSN98125A patent/TNSN98125A1/fr unknown
- 1998-07-01 CO CO98037140A patent/CO4940402A1/es unknown
- 1998-07-01 HR HR980379A patent/HRP980379B1/xx not_active IP Right Cessation
1999
- 1999-11-23 BG BG103915A patent/BG103915A/xx unknown
- 1999-11-23 IS IS5265A patent/IS5265A/is unknown
- 1999-12-23 OA OA9900305A patent/OA11245A/en unknown
- 1999-12-28 NO NO996518A patent/NO996518L/no not_active Application Discontinuation
2006
- 2006-01-03 AR ARP060100016A patent/AR065827A2/es unknown

Also Published As

Publication number	Publication date
BR9810403A (pt)	2000-08-29
KR100412327B1 (ko)	2003-12-31
SK180499A3 (en)	2001-08-06
HUP0002296A3 (en)	2001-11-28
ID23503A (id)	2000-04-27
CA2290966A1 (fr)	1999-01-14
TR199903280T2 (xx)	2000-11-21
AU7544998A (en)	1999-01-25
EA002482B1 (ru)	2002-06-27
KR20010014043A (ko)	2001-02-26
KR20040004367A (ko)	2004-01-13
NZ501251A (en)	2001-09-28
OA11245A (en)	2003-07-23
HRP980379B1 (en)	2003-04-30
HUP0002296A2 (hu)	2001-10-28
WO1999001121A1 (fr)	1999-01-14
IL133080A0 (en)	2001-03-19
NZ513456A (en)	2003-02-28
AR015919A1 (es)	2001-05-30
NO996518D0 (no)	1999-12-28
EA199900964A1 (ru)	2000-08-28
PE88699A1 (es)	1999-09-20
AR065827A2 (es)	2009-07-08
IS5265A (is)	1999-11-23
KR100446366B1 (ko)	2004-09-01
UY25067A1 (es)	2000-12-29
NO996518L (no)	2000-02-29
AP9801281A0 (en)	1998-06-30
MY129175A (en)	2007-03-30
HK1026630A1 (en)	2000-12-22
BG103915A (en)	2000-07-31
CA2290966C (fr)	2005-12-20
TNSN98125A1 (fr)	2005-03-15
EP0999830A1 (fr)	2000-05-17
CO4940402A1 (es)	2000-07-24
IL152330A0 (en)	2003-05-29
PA8454401A1 (es)	2000-05-24
US6517866B1 (en)	2003-02-11
TWI241188B (en)	2005-10-11
PL337806A1 (en)	2000-09-11
JP2000514101A (ja)	2000-10-24
CN1256085C (zh)	2006-05-17
HRP980379A2 (en)	1999-04-30
AU739261B2 (en)	2001-10-11
CN1261793A (zh)	2000-08-02
AP1526A (en)	2006-01-03

Publication	Publication Date	Title
DZ2923A1 (fr)	2004-03-01	Formulations pharmaceutiques d'inhibiteurs de pde-5 de gmpc à libération contrôlée, et procédé pour leur préparation.
MA26536A1 (fr)	2004-12-20	Association de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation.
FR2776520B1 (fr)	2000-05-05	Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
DZ2786A1 (fr)	2003-12-01	Préparation pharmaceutique de sildénafil à délitement oral et procédé por sa production.
EP0741580A4 (fr)	2001-07-11	Liberation controlee de substances pharmaceutiquement actives pour l'immunotherapie
FR2722984B1 (fr)	1996-10-18	Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
DZ2523A1 (fr)	2003-02-01	Formulations pharmaceutiques contenant du voriconazole et procédé pour leur préparation.
FR2650182B1 (fr)	1992-05-15	Procede de preparation d'une composition pharmaceutique sous forme de microparticules
NO20004915L (no)	2000-11-08	Transdermalt terapeutisk system som inneholder en D2-agonist og som tilveiebringes for behandling av Parkinsons sykdom og en fremgangsmÕte for dets fremstilling
BR9609701A (pt)	1999-03-23	Composição farmacéutica composto e processo para a preparação de compostos
DZ2410A1 (fr)	2003-01-04	Dérivés d'acide arylsulfonylaminohydroxamique procédé pour leur préparation et compositions pharmaceutiques
BR9611986A (pt)	1999-02-17	Compostos processo para a preparação dos mesmos composição farmcéutica e utilização dos compostos
DZ2600A1 (fr)	2003-03-01	Associations pharmaceutiques d'amlodipine et d'unestatine et procédé pour leur préparation.
FR2732223B1 (fr)	1997-06-13	Composition pharmaceutique pour administration transdermique
FR2779651B1 (fr)	2001-04-20	Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero
BR9607346A (pt)	1997-12-30	Composto utilizaç o de um composto composiç o farmacéutica e processo para o tratamento de um mamifero e para e preparaç o de compostos
EP0752405A3 (fr)	1997-03-26	Procédé pour la préparation de phénol
BR9711225A (pt)	1999-08-17	Composi-{es de propentofilina transd-rmica para o tratamento do mal de alzheimer
BR9610733A (pt)	1999-07-13	Composto processos para a preparação do mesmo e para o tratamento de um mamífero composição farmacêutica e utilização de um composto
DZ2547A1 (fr)	2003-02-08	Formes posologiques de sertraline à libération prolongée.
OA08192A (fr)	1987-10-30	Nouveau procédé d'obtention de formes pharmaceutiques à libération prolongée.
FR2796940B1 (fr)	2005-04-08	Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
DZ2544A1 (fr)	2003-02-08	Formes posologiques de sertraline et procédé pour leur préparation.
MA24183A1 (fr)	1997-12-31	Procede pour la preparation de compositions pharmaceutiques a base de diclofenac
MA23663A1 (fr)	1996-04-01	Procede de preparation de formulations pharmaceutiques